Phaseline

Companies › Neogap Therapeutics

Neogap Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
pTTL (personal tumour-trained lymphocytes)
Autologous cell product: patient-derived tumor-draining lymph node T cells expanded in vit
–Phase 1Colorectal CancerDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05908643pTTL (personal tumour-trained lymphocytes)Phase 1Colorectal CancerOncologyDec 2030

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.